According to a BSE filing, the company's "Board of Directors" in a meeting held on Monday approved the proposal for a buyback of up to 3,450,000 equity shares of Rs 5 each at a price of Rs 670 per equity share.
"The buyback would be subject to approval of the share-holders of the company by way of a special resolution through postal ballot and all other applicable statutory approvals," the company informed the BSE in a regulatory filing.
"The board has constituted a buyback committee and delegated its powers to the buyback committee to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary expedient, usual or proper in connection with the buyback."
Besides the buyback announcement, the pharma firm further said that it has appointed Trivikram Guda, as Company Secretary and as the Compliance Officer for the purpose of buyback of shares.
The company's scrip at the BSE traded down Rs 52.20 or 7.65 per cent at Rs 630.40 from its previous close of Rs 682.60 on last Friday.
(This story has not been edited by Social News XYZ staff and is auto-generated from a syndicated feed.)
About VDC
Doraiah Chowdary Vundavally is a Software engineer at VTech . He is the news editor of SocialNews.XYZ and Freelance writer-contributes Telugu and English Columns on Films, Politics, and Gossips. He is the primary contributor for South Cinema Section of SocialNews.XYZ. His mission is to help to develop SocialNews.XYZ into a News website that has no bias or judgement towards any.